Maximize your research potentialin partnership with RD-Biotech

RD-Biotech is a biotechnology company that offers tailor-made solutions in Molecular Biology, Immunology and Cellular Engineering, as part of Research & Development, pre-clinical or clinical studies. Since its creation in 2002, RD-Biotech provides technical skills and scientific know-how for a personalized, responsive and quality service, and with complete confidentiality.


RD-Biotech is at your disposal to meet your needs and accelerate your research.
From a feasibility study to the development and production of your biological reagents: DNA, antibodies, recombinant proteins, cells…

RD-Biotech offers you quality and ready-to-use products, available in catalogue and bulk format…

"We have the ambition to become a partner of choicein the realization of your projects by saving you timeand allowing you to reduce your operating costs"

— Philippe Dulieu, President of RD-Biotech
RD-Biotech, a complete platform from DNA to antibody

For your antibody development projects, for applications in immunotherapy, diagnostics, research: contact our team of experts in molecular biology and antibody engineering.

Contact us for more information!

RD-Biotech is here to help you in your projects related to Covid-19!

Development / Production of monoclonal or recombinant antibodies - Expression vector construction - Antigen expression - DNA plasmid production...

Contact us for more information!

Our sister company, Diaclone, is now part of the Medix Biochemica group

Biotech Investissement ( separates from its subsidiary Diaclone by selling it to Medix Biochemica.

The arrival of Diaclone in the Medix group will allow it to access new international markets, and therefore to continue its growth in the In Vitro Diagnostics (IVD) market.

Our group will now focus on the development of biomanufacturing services for plasmid DNAs, antibodies and recombinant proteins with in particular the upcoming construction of a new DNA production unit, GMP grade (BPF) at RD-BIOTECH.

Link to the press release: Biotech Investissement communication
Contact us for more information!